Autologous stem cell therapy - Proteonomix

Drug Profile

Autologous stem cell therapy - Proteonomix

Alternative Names: UMK-121

Latest Information Update: 10 Jan 2013

Price : $50

At a glance

  • Originator Proteonomix; StromaCel
  • Developer Proteonomix
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver failure

Most Recent Events

  • 08 Jan 2013 Phase-I clinical trials in Liver failure in USA (Parenteral)
  • 08 Jan 2013 Proteonomix plans clinical trials for Cancer and Cardiovascular disorders
  • 14 Sep 2012 Proteonomix establishes an agreement with the University of Medicine and Dentistry of New Jersey to conduct a phase I trial of UMK 121 for Liver failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top